Eintrag weiter verarbeiten
Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific anti...
Gespeichert in:
| Zeitschriftentitel: | International Journal of Cancer |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , |
| In: | International Journal of Cancer, 118, 2006, 5, S. 1234-1240 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Steuber, Thomas Vickers, Andrew J. Haese, Alexander Becker, Charlotte Pettersson, Kim Chun, Felix K.‐H. Kattan, Michael W. Eastham, James A. Scardino, Peter T. Huland, Hartwig Lilja, Hans Steuber, Thomas Vickers, Andrew J. Haese, Alexander Becker, Charlotte Pettersson, Kim Chun, Felix K.‐H. Kattan, Michael W. Eastham, James A. Scardino, Peter T. Huland, Hartwig Lilja, Hans |
|---|---|
| author |
Steuber, Thomas Vickers, Andrew J. Haese, Alexander Becker, Charlotte Pettersson, Kim Chun, Felix K.‐H. Kattan, Michael W. Eastham, James A. Scardino, Peter T. Huland, Hartwig Lilja, Hans |
| spellingShingle |
Steuber, Thomas Vickers, Andrew J. Haese, Alexander Becker, Charlotte Pettersson, Kim Chun, Felix K.‐H. Kattan, Michael W. Eastham, James A. Scardino, Peter T. Huland, Hartwig Lilja, Hans International Journal of Cancer Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum Cancer Research Oncology |
| author_sort |
steuber, thomas |
| spelling |
Steuber, Thomas Vickers, Andrew J. Haese, Alexander Becker, Charlotte Pettersson, Kim Chun, Felix K.‐H. Kattan, Michael W. Eastham, James A. Scardino, Peter T. Huland, Hartwig Lilja, Hans 0020-7136 1097-0215 Wiley Cancer Research Oncology http://dx.doi.org/10.1002/ijc.21474 <jats:title>Abstract</jats:title><jats:p>Most models to predict biochemical recurrence (BCR) of prostate cancer use pretreatment serum prostate‐specific antigen (PSA), clinical stage and prostate biopsy Gleason grade. We investigated whether human glandular kallikrein 2 (hK2) and free prostate‐specific antigen (fPSA) measured in pretreatment serum enhance prediction. We retrospectively measured total PSA (tPSA), fPSA and hK2 in preoperative serum samples from 461 men with localized prostate cancer treated with radical prostatectomy between 1999 and 2001. We developed a regression model to predict BCR using preoperative tPSA, clinical stage and biopsy Gleason grade. We then compared the predictive accuracy of this “base” model with a model with fPSA and hK2 as additional predictors. BCR was observed in 90 patients (20%), including 48 patients with a pretreatment tPSA ≤ 14 ng/ml (13%), and 28 patients (10%) with a pretreatment tPSA ≤ 10 ng/ml. Overall, the predictive accuracy of the base model (bootstrap‐corrected concordance index of 0.813) was not improved after the addition of fPSA or hK2 (0.818). However, for men with moderate tPSA‐elevation (tPSA ≤ 10 ng/ml), addition of fPSA and hK2 data increased predictive accuracy (from a base model concordance index of 0.756–0.815, <jats:italic>p</jats:italic> = 0.005). The improvement in accuracy was not sensitive to the threshold for “moderately elevated” PSA. For patients with a moderate tPSA‐elevation (tPSA ≤ 10 ng/ml), which closely corresponds to concurrent disease demographics, BCR‐prediction was enhanced when fPSA and hK2 were added to the conventional model. Measurements of fPSA and hK2 improve on our ability to counsel patients prior to treatment as to their risk of BCR. © 2005 Wiley‐Liss, Inc.</jats:p> Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum International Journal of Cancer |
| doi_str_mv |
10.1002/ijc.21474 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9pamMuMjE0NzQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9pamMuMjE0NzQ |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
Wiley, 2006 |
| imprint_str_mv |
Wiley, 2006 |
| issn |
0020-7136 1097-0215 |
| issn_str_mv |
0020-7136 1097-0215 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
steuber2006riskassessmentforbiochemicalrecurrencepriortoradicalprostatectomysignificantenhancementcontributedbyhumanglandularkallikrein2hk2andfreeprostatespecificantigenpsainmenwithmoderatepsaelevationinserum |
| publishDateSort |
2006 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
International Journal of Cancer |
| source_id |
49 |
| title |
Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum |
| title_unstemmed |
Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum |
| title_full |
Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum |
| title_fullStr |
Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum |
| title_full_unstemmed |
Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum |
| title_short |
Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum |
| title_sort |
risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hk2) and free prostate specific antigen (psa) in men with moderate psa‐elevation in serum |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1002/ijc.21474 |
| publishDate |
2006 |
| physical |
1234-1240 |
| description |
<jats:title>Abstract</jats:title><jats:p>Most models to predict biochemical recurrence (BCR) of prostate cancer use pretreatment serum prostate‐specific antigen (PSA), clinical stage and prostate biopsy Gleason grade. We investigated whether human glandular kallikrein 2 (hK2) and free prostate‐specific antigen (fPSA) measured in pretreatment serum enhance prediction. We retrospectively measured total PSA (tPSA), fPSA and hK2 in preoperative serum samples from 461 men with localized prostate cancer treated with radical prostatectomy between 1999 and 2001. We developed a regression model to predict BCR using preoperative tPSA, clinical stage and biopsy Gleason grade. We then compared the predictive accuracy of this “base” model with a model with fPSA and hK2 as additional predictors. BCR was observed in 90 patients (20%), including 48 patients with a pretreatment tPSA ≤ 14 ng/ml (13%), and 28 patients (10%) with a pretreatment tPSA ≤ 10 ng/ml. Overall, the predictive accuracy of the base model (bootstrap‐corrected concordance index of 0.813) was not improved after the addition of fPSA or hK2 (0.818). However, for men with moderate tPSA‐elevation (tPSA ≤ 10 ng/ml), addition of fPSA and hK2 data increased predictive accuracy (from a base model concordance index of 0.756–0.815, <jats:italic>p</jats:italic> = 0.005). The improvement in accuracy was not sensitive to the threshold for “moderately elevated” PSA. For patients with a moderate tPSA‐elevation (tPSA ≤ 10 ng/ml), which closely corresponds to concurrent disease demographics, BCR‐prediction was enhanced when fPSA and hK2 were added to the conventional model. Measurements of fPSA and hK2 improve on our ability to counsel patients prior to treatment as to their risk of BCR. © 2005 Wiley‐Liss, Inc.</jats:p> |
| container_issue |
5 |
| container_start_page |
1234 |
| container_title |
International Journal of Cancer |
| container_volume |
118 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792337311729451017 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:14:19.753Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Risk+assessment+for+biochemical+recurrence+prior+to+radical+prostatectomy%3A+Significant+enhancement+contributed+by+human+glandular+kallikrein+2+%28hK2%29+and+free+prostate+specific+antigen+%28PSA%29+in+men+with+moderate+PSA%E2%80%90elevation+in+serum&rft.date=2006-03-01&genre=article&issn=1097-0215&volume=118&issue=5&spage=1234&epage=1240&pages=1234-1240&jtitle=International+Journal+of+Cancer&atitle=Risk+assessment+for+biochemical+recurrence+prior+to+radical+prostatectomy%3A+Significant+enhancement+contributed+by+human+glandular+kallikrein+2+%28hK2%29+and+free+prostate+specific+antigen+%28PSA%29+in+men+with+moderate+PSA%E2%80%90elevation+in+serum&aulast=Lilja&aufirst=Hans&rft_id=info%3Adoi%2F10.1002%2Fijc.21474&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792337311729451017 |
| author | Steuber, Thomas, Vickers, Andrew J., Haese, Alexander, Becker, Charlotte, Pettersson, Kim, Chun, Felix K.‐H., Kattan, Michael W., Eastham, James A., Scardino, Peter T., Huland, Hartwig, Lilja, Hans |
| author_facet | Steuber, Thomas, Vickers, Andrew J., Haese, Alexander, Becker, Charlotte, Pettersson, Kim, Chun, Felix K.‐H., Kattan, Michael W., Eastham, James A., Scardino, Peter T., Huland, Hartwig, Lilja, Hans, Steuber, Thomas, Vickers, Andrew J., Haese, Alexander, Becker, Charlotte, Pettersson, Kim, Chun, Felix K.‐H., Kattan, Michael W., Eastham, James A., Scardino, Peter T., Huland, Hartwig, Lilja, Hans |
| author_sort | steuber, thomas |
| container_issue | 5 |
| container_start_page | 1234 |
| container_title | International Journal of Cancer |
| container_volume | 118 |
| description | <jats:title>Abstract</jats:title><jats:p>Most models to predict biochemical recurrence (BCR) of prostate cancer use pretreatment serum prostate‐specific antigen (PSA), clinical stage and prostate biopsy Gleason grade. We investigated whether human glandular kallikrein 2 (hK2) and free prostate‐specific antigen (fPSA) measured in pretreatment serum enhance prediction. We retrospectively measured total PSA (tPSA), fPSA and hK2 in preoperative serum samples from 461 men with localized prostate cancer treated with radical prostatectomy between 1999 and 2001. We developed a regression model to predict BCR using preoperative tPSA, clinical stage and biopsy Gleason grade. We then compared the predictive accuracy of this “base” model with a model with fPSA and hK2 as additional predictors. BCR was observed in 90 patients (20%), including 48 patients with a pretreatment tPSA ≤ 14 ng/ml (13%), and 28 patients (10%) with a pretreatment tPSA ≤ 10 ng/ml. Overall, the predictive accuracy of the base model (bootstrap‐corrected concordance index of 0.813) was not improved after the addition of fPSA or hK2 (0.818). However, for men with moderate tPSA‐elevation (tPSA ≤ 10 ng/ml), addition of fPSA and hK2 data increased predictive accuracy (from a base model concordance index of 0.756–0.815, <jats:italic>p</jats:italic> = 0.005). The improvement in accuracy was not sensitive to the threshold for “moderately elevated” PSA. For patients with a moderate tPSA‐elevation (tPSA ≤ 10 ng/ml), which closely corresponds to concurrent disease demographics, BCR‐prediction was enhanced when fPSA and hK2 were added to the conventional model. Measurements of fPSA and hK2 improve on our ability to counsel patients prior to treatment as to their risk of BCR. © 2005 Wiley‐Liss, Inc.</jats:p> |
| doi_str_mv | 10.1002/ijc.21474 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9pamMuMjE0NzQ |
| imprint | Wiley, 2006 |
| imprint_str_mv | Wiley, 2006 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 0020-7136, 1097-0215 |
| issn_str_mv | 0020-7136, 1097-0215 |
| language | English |
| last_indexed | 2024-03-01T15:14:19.753Z |
| match_str | steuber2006riskassessmentforbiochemicalrecurrencepriortoradicalprostatectomysignificantenhancementcontributedbyhumanglandularkallikrein2hk2andfreeprostatespecificantigenpsainmenwithmoderatepsaelevationinserum |
| mega_collection | Wiley (CrossRef) |
| physical | 1234-1240 |
| publishDate | 2006 |
| publishDateSort | 2006 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | International Journal of Cancer |
| source_id | 49 |
| spelling | Steuber, Thomas Vickers, Andrew J. Haese, Alexander Becker, Charlotte Pettersson, Kim Chun, Felix K.‐H. Kattan, Michael W. Eastham, James A. Scardino, Peter T. Huland, Hartwig Lilja, Hans 0020-7136 1097-0215 Wiley Cancer Research Oncology http://dx.doi.org/10.1002/ijc.21474 <jats:title>Abstract</jats:title><jats:p>Most models to predict biochemical recurrence (BCR) of prostate cancer use pretreatment serum prostate‐specific antigen (PSA), clinical stage and prostate biopsy Gleason grade. We investigated whether human glandular kallikrein 2 (hK2) and free prostate‐specific antigen (fPSA) measured in pretreatment serum enhance prediction. We retrospectively measured total PSA (tPSA), fPSA and hK2 in preoperative serum samples from 461 men with localized prostate cancer treated with radical prostatectomy between 1999 and 2001. We developed a regression model to predict BCR using preoperative tPSA, clinical stage and biopsy Gleason grade. We then compared the predictive accuracy of this “base” model with a model with fPSA and hK2 as additional predictors. BCR was observed in 90 patients (20%), including 48 patients with a pretreatment tPSA ≤ 14 ng/ml (13%), and 28 patients (10%) with a pretreatment tPSA ≤ 10 ng/ml. Overall, the predictive accuracy of the base model (bootstrap‐corrected concordance index of 0.813) was not improved after the addition of fPSA or hK2 (0.818). However, for men with moderate tPSA‐elevation (tPSA ≤ 10 ng/ml), addition of fPSA and hK2 data increased predictive accuracy (from a base model concordance index of 0.756–0.815, <jats:italic>p</jats:italic> = 0.005). The improvement in accuracy was not sensitive to the threshold for “moderately elevated” PSA. For patients with a moderate tPSA‐elevation (tPSA ≤ 10 ng/ml), which closely corresponds to concurrent disease demographics, BCR‐prediction was enhanced when fPSA and hK2 were added to the conventional model. Measurements of fPSA and hK2 improve on our ability to counsel patients prior to treatment as to their risk of BCR. © 2005 Wiley‐Liss, Inc.</jats:p> Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum International Journal of Cancer |
| spellingShingle | Steuber, Thomas, Vickers, Andrew J., Haese, Alexander, Becker, Charlotte, Pettersson, Kim, Chun, Felix K.‐H., Kattan, Michael W., Eastham, James A., Scardino, Peter T., Huland, Hartwig, Lilja, Hans, International Journal of Cancer, Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum, Cancer Research, Oncology |
| title | Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum |
| title_full | Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum |
| title_fullStr | Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum |
| title_full_unstemmed | Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum |
| title_short | Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum |
| title_sort | risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hk2) and free prostate specific antigen (psa) in men with moderate psa‐elevation in serum |
| title_unstemmed | Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1002/ijc.21474 |